Mao Huaying, Yang Fan
Clinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
Clinical Laboratory, Huzhou Maternity and Child Health Care Hospital, Huzhou, Zhejiang, China.
Front Oncol. 2023 Jun 5;13:1193962. doi: 10.3389/fonc.2023.1193962. eCollection 2023.
The prognosis of several malignancies has been influenced by the systemic immune-inflammation index (SII); however, its association with the prognostic outcome of ovarian cancer (OC) remains controversial. The present meta-analysis focused on the systemic and comprehensive identification of the role of SII in predicting OC prognosis.
We searched the Web of Science, PubMed, Cochrane Library, Embase, and China National Knowledge Infrastructure (CNKI) from inception until March 6, 2023. To predict the prognostic value of SII for overall survival (OS) and progression-free survival (PFS) in patients with OC, we calculated pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs).
The meta-analysis included six studies involving 1546 patients. The combined results showed that a high SII was significantly associated with poor OS (HR=2.70, 95% CI=1.98-3.67, p<0.001) and poor PFS (HR=2.71, 95% CI=1.78-4.12, p<0.001) in OC patients. These results were confirmed using subgroup and sensitivity analyses.
Our results concluded that a high SII significantly predicted poor OS and PFS in patients with OC. Therefore, it can be speculated that the SII may have an independent effect on the prognosis of OC.
多种恶性肿瘤的预后受到全身免疫炎症指数（SII）的影响；然而，其与卵巢癌（OC）预后结果的关联仍存在争议。本荟萃分析着重于系统全面地确定SII在预测OC预后中的作用。
我们检索了从创刊至2023年3月6日的Web of Science、PubMed、Cochrane图书馆、Embase和中国知网（CNKI）。为预测SII对OC患者总生存期（OS）和无进展生存期（PFS）的预后价值，我们计算了合并风险比（HRs）及相应的95%置信区间（CIs）。
该荟萃分析纳入了6项研究，共1546例患者。合并结果显示，高SII与OC患者较差的OS（HR = 2.70，95% CI = 1.98 - 3.67，p < 0.001）和较差的PFS（HR = 2.71，95% CI = 1.78 - 4.12，p < 0.001）显著相关。这些结果通过亚组分析和敏感性分析得到了证实。
我们的结果表明，高SII显著预测OC患者较差的OS和PFS。因此，可以推测SII可能对OC的预后有独立影响。
